Home / Resource Library / Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naive (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis
Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naive (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis